Concepta PLC (LON:CPT) has signed two more distributor agreements in China for its myLotus product, which will target the early pregnancy and fertility markets.
In a statement Concepta said Huanzhong Biotech and Wanma Technology have both signed 3-year exclusive distribution agreements, which will cover the provinces of Hebei near Beijing and the Shanghai area respectively.
READ: Fertility specialist Concepta primed and ready for next stage of its development
A previous agreement with ThinkBrio covers Beijing and Lianoing and with these two additional agreements Concepta's product will be available to 147mln people.
Erik Henau, Concepta’s chief executive, added that an event is now being planned in China to follow up strong hospital evaluation results.
Dr Yin Hui Rong, principal investigator at the Changhai Hospital Reproductive Centre, said myLotus was producing results comparing with larger laboratory-style equipment, opening up the potential for it to be used at home.
READ: Concepta marks first myLotus shipment into China
Following the hospital evaluation, Huanzhong Biotech and Wanma will target the "early pregnancy" group alongside the "unexplained infertility" target group, which is an additional market of 2.3mln women a year.
Erik Henau, added: "Following the final conclusion of the evaluation, an event will be held in China for a large number of potential distributors where we will exhibit the myLotus product. We expect to announce further distribution agreement signings following this event."